Looking Ahead: Integrating Emerging Therapies and Tools in Early-Stage Alzheimer’s Disease


Sharon Cohen, MD, FRCPC
Behavioural Neurologist, Founder and Medical Director, Toronto Memory Program, Toronto, Canada
Sharon Cohen, MD, FRCPC

r. Sharon Cohen, MD, FRCP, is a behavioural neurologist and the medical director of the Toronto Memory Program, a community-based medical facility which she established in 1996 for the purpose of enhancing diagnosis and treatment for individuals with Alzheimer’s disease and related disorders. Her memory clinic and dementia research site are among the most active in Canada. Dr. Cohen has over 28 years of experience in clinical research and has been a site primary investigator for over 180 pharmacological trials in dementia, including phase 1 trials. She represents Canada on international advisory boards and steering committees and is a consultant to a wide range of stakeholders including government organizations and patient advocacy groups. She is a frequent lecturer and contributes to media events including those on medical ethics. Additionally, she is known for her advocacy of individuals with neurodegenerative diseases.

Despite holding academic and hospital appointments, Dr. Cohen chooses to practice in the community, in keeping with her belief that dementia care and clinical research are best offered in the real-world setting.

Mark Brody, MD, CPI
President, Principal Investigator, Brain Matters Research, Delray Beach, FL
Mark Brody, MD, CPI

Dr. Mark Brody is President of Brain Matters Research, one of the largest private clinical research facilities in the country, specializing in Alzheimer’s disease diagnosis, treatment, and research. He is a nationally recognized expert in both Alzheimer’s disease and stroke, as well as the Principal Investigator in numerous clinical trials seeking to prevent and treat Alzheimer’s disease. Dr. Brody is in private practice in Delray Beach, specializing in memory disorders and stroke prevention. He is one of a small group of neurologists whose career spans academic and clinical practice as well as clinical research.

He is an author, humorist, lecturer, and health care entrepreneur, and serves on the medical advisory boards of numerous pharmaceutical companies. Dr. Brody is an acknowledged industry thought leader in the development of new clinical research protocols.

Pierre N. Tariot, MD
Director, Banner Alzheimer's Institute
Research Professor of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ
Pierre N. Tariot, MD

Dr. Tariot is board certified in internal medicine and psychiatry with added qualifications in geriatrics. He was as a Fellow at the National Institute of Mental Health (NIMH) Intramural Research Program, then served as a faculty member at the University of Rochester Medical Center and, since 2006, he has served as Director of the Banner Alzheimer’s Institute in Phoenix. He is also a Research Professor of Psychiatry at the University of Arizona College of Medicine. His work has focused on care and study of people with and at risk for Alzheimer’s disease, with special emphasis on design and implementation of clinical trials for prevention and treatment, development of biomarkers, and demonstration of effective dementia care. He has published over 400 papers on these topics, including articles regarding studies that have led to FDA approval of new medications. Dr. Tariot serves as co-director of the Alzheimer’s Prevention Initiative (API). His research affiliations include the National Institute on Aging (NIA), the NIMH, and the Alzheimer’s Association.

Statement of Need

Alzheimer’s disease (AD), a heterogeneous, neurodegenerative condition with an insidious onset and slow progression, is the leading cause of disability and morbidity as well as the sixth-leading cause of death in the United States. Diagnosing AD is often complicated due to its varied clinical symptomatology and unknown etiology, and currently only symptomatic therapies are available.

Recent clinical trials investigating disease-modifying therapies (DMTs) that could slow or reverse the progression of AD have shown great promise. These recent advances in the development of AD therapies have led to the need for health care providers (HCPs) to be knowledgeable about the pathogenesis of AD and its potential implications for treatment, current diagnostic criteria for early recognition, recent advances in the field of imaging in AD, and the latest clinical evidence on emerging DMTs from select patient populations.

This Live and OnDemand webcast will feature interactive and lively discussion among specialists who treat patients with AD, with a focus on recognizing early-stage symptoms of AD, the potential role of emerging therapies in treating patients with early-stage AD, and integrating multimodal imaging strategies into the diagnostic process.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Recognize the clinical presentation of early-stage AD.
  • Assess the safety and efficacy of emerging therapies and their potential role in the treatment continuum of patients with early-stage AD.
  • Integrate multimodal imaging and biomarker strategies into the diagnostic process ofAD to inform clinical decision-making.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Recognize the clinical presentation of early-stage AD.
  • Discuss the safety and efficacy of emerging therapies and their potential role in the treatment continuum of patients with early-stage AD.
  • Summarize how to integrate multimodal imaging and biomarker strategies into the diagnostic process of AD to inform clinical decision-making.

Financial Support

Supported by educational grants from Biogen MA, Inc. and Eisai Inc.

Target Audience

Primary care physicians, neurologists, psychiatrists, geriatricians, nurse practitioners, PAs, nurses and pharmacists

Credit Information

Physicians (ACCME) 1.5

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.5 contact hours. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.5

This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit.
Enduring: JA0007185-0000-21-149-H01-P


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Cohen reports that she receives research support from AbbVie Inc.; AgeneBio, Inc.; Eisai Co., Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, USA Inc.; Novartis; and RetiSpec Inc. She is on the advisory committee for Biogen and ProMIS Neurosciences. She is a consultant for Biogen; Black Diamond Therapeutics, Inc.; Cogstate; Eli Lilly and Company; and RetiSpec Inc.

Dr. Brody reports he receives grants from Biogen and Eisai Inc. He is a stockholder (directly purchased) in Biogen.

Dr. Tariot reports that he receives research support from AbbVie Inc.; Avanir Pharmaceuticals, Inc.; Biogen MA, Inc.; Cortexyme; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, USA Inc.; Merck & Co., Inc.; and Novartis. He is on the advisory committee for ACADIA Pharmaceuticals Inc.; Axsome Therapeutics, Inc.; BioXcel Therapeutics, Inc.; Cortexyme; Eisai Co., Ltd.; and Syneos Health. He is a consultant for Astex Pharmaceuticals; eNova; Immune; and Otsuka America Pharmaceutical, Inc. He is a stock shareholder (directly purchased) in Adamas Pharmaceuticals, Inc. He receives other financial support from Alzheimer’s Association; Alzheimer’s Foundation; Arizona Department of Health Services; Banner Health; Flinn Foundation; FBRI; Geoffrey Beene Foundation; GHR Foundation; National Institute on Aging; and NOMIS Foundation.

Disclosures were obtained from the CME Outfitters, LLC staff;  no disclosures to report:

  • Jeffrey Helfand, DO (peer reviewer)
  • Mae Ochoa, RPh (peer reviewer)
  • Rachel Speer, PhD (planning committee)
  • Susan Perry (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

Looking Ahead: Integrating Emerging Therapies and Tools in Early-Stage Alzheimer’s Disease
Event Date: 10/08/2020